3Q EARNINGS: Yervoy boosts Bristol-Myers sales, Opdivo dominates pipeline
This article was originally published in Scrip
Executive Summary
Yervoy (ipilimumab) had the fastest sales growth rate of any Bristol-Myers Squibb cancer drug in the third quarter, but investors are focused on the company's next potential immunotherapy blockbuster Opdivo (nivolumab), which could win US FDA approval early next year.